Overview

Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.

Status:
RECRUITING
Trial end date:
2026-03-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe HS.
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Huaota Biopharmaceutical Co., Ltd.
Collaborator:
Dermatology Hospital affiliated to Shandong First Medical University